EyePoint Secures Two US Patents for DEXYCU

April 13, 2018: By Jon Swedien

EyePoint Pharmaceuticals

The US Patent and Trademark Office (USPTO) issued EyePoint Pharmaceuticals a notice of allowance for two patents covering DEXYCU, the Watertown, Massachusetts-based company (formerly pSivida) announced April 12.

DEXYCU (dexamethasone intraocular suspension) is FDA-approved for the treatment of postoperative inflammation associated with cataract surgery.

The first patent includes claims relating to a method of treating inflammation of an eye following cataract surgery by delivering extremely small (4-6µL) amounts of dexamethasone in triethyl acetyl citrate, EyePoint said. Once issued, the patent will expire in 2034, the company said.

The second patent includes claims relating to loading and delivering a small dose volume from an injection syringe. Once issued, it will expire in 2032.

After issuing a notice of allowance, the USPTO requires applicants to pay fees before it issues patents.

DEXYCU delivers a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating a patient’s need to take medicated eye drops several times a day for several weeks on a titrated schedule, EyePoint said.

DEXYCU employs the firm’s Verisome technology to dispense a biodegradable extended-release formulation of dexamethasone into the anterior chamber of the eye, EyePoint said.

EyePoint was formed after pSivida Corp acquired privately held Icon Bioscience of Newark, California, in March and rebranded.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023